ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
How do these antibody molecules distinguish from current, clinically approved immuno-therapies ?
ARPA Bio uses several proprietary antibodies to target key molecular events (seeds) during early Aβ aggregation. This strategy places us at a unique position, enabling early diagnostics and therapeutic intervention, by targeting the root cause of the pathophysiology of the disease. Our therapeutic approach aims at selective targeting of early amyloid (Aβ) seeds and therefore inhibiting a time dependent formation of neurotoxic oligomers or protofibrils, which represent targets, of more advanced disease stages.
